Search

The purpose of this study was to examine the fermentation of A. membranaceus by L. plantarum and its effects on broiler chickens. L. plantarum solid-state fermentation was employed to solve the problem of releasing the active components of A. membranaceus. The effect of L. plantarum on astragalus was examined by measuring the contents of protein, carbohydrate, calycoflavone, and formononetin in A. membranaceus before and after fermentation. The effect of A. membranaceus on L. plantarum was demonstrated by detecting the changes in galactosidase in L. plantarum before and after fermentation. Fermented A. membranaceus was fed to broiler chickens, and the indices of growth performance, antioxidants, immune function, and intestinal short-chain fatty acids were recorded. The results showed that the cellulose and pectin on the surface of A. membranaceus were decomposed by L. plantarum solid-state fermentation, and the macromolecular proteins were degraded into small molecules. A. membranaceus increased the content of galactosidase in L. plantarum. Solid-state fermentation increased the contents of functional sugars, calycosin, and formononetin in A. membranaceus. Fermentation of A. membranaceus significantly improved the production performance of broilers as well as the antioxidant index, immune index, intestinal morphology, and intestinal short-chain fatty acid content. [ABSTRACT FROM AUTHOR]

Introduction: A long-term high-fat diet (HFD) cause obesity and infertility through hypothalamic inflammation and insulin resistance, leading to metabolic abnormalities and ovulation dysfunction. The sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a treatment for type 2 diabetic patients, regulating adipose tissue metabolism, hypothalamic inflammation, and ovulation in women with polycystic ovary syndrome (PCOS). The study aimed to investigate the pharmacological effects of dapagliflozin on improving insulin resistance, energy metabolism, sex hormones, and fertility in female mice following prolonged consumption of HFD. Methods: At 6 weeks of age, female mice were fed a HFD and treated with dapagliflozin. Serum hormone concentrations and inflammatory factors in mice aged 28 weeks or 38 weeks were quantified using ultrasensitive enzyme-linked immunosorbent assays (ELISAs). Metabolic parameters were also assessed and documented at different stages of the experiment. At 34 weeks of age, half of the experimental mice in each of the four groups fed with standard chow were mated with male mice. Pregnancy rate, abortion rate, pregnancy-related deaths, and perinatal outcomes were systematically recorded. Results: After 16 weeks of HFD feeding, dapagliflozin significantly attenuated visceral fat deposition, weight gain, glucose intolerance, and insulin resistance induced by the diet. However, these effects diminished after 32 weeks. Unexpectedly, neither HFD nor dapagliflozin treatment elicited any significant changes in serum IL-6 and TNFα levels. Throughout the experiment period, dapagliflozin exhibited favorable effects on reproductive function along with insulin sensitivity and luteinizing hormone (LH) release from the pituitary gland. Discussion: In conclusion, this study demonstrates that dapagliflozin alleviated HFD-induced reproductive dysfunction independently of obesity, peripheral tissue insulin resistance, and systemic inflammation, suggesting its potential as a promising treatment for diet-related ovulation disorders. [ABSTRACT FROM AUTHOR]

Background: High fat consumption is a known risk factor for the development of type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been found to possess anti-inflammatory and neuroprotective properties. However, the cognitive effects and mechanisms of SGLT2is on female mice fed with a high-fat diet remain unknown., Objective: This study aimed to investigate the impacts of dapagliflozin on metabolism, cognition, neuroinflammation, insulin resistance, and microglial activation in female mice fed a HFD., Methods: Dapagliflozin (1 mg/kg) was administered to HFD-fed mice for 24 weeks. Body weight, glucose tolerance, and insulin resistance were assessed. Additionally, all mice were subjected to the Morris water maze (MWM) and one-trial Y-maze tests. The levels of metabolic hormones and cytokines were analyzed using ELISA kits. The levels of phosphorylated tau (p-tau) protein in the hippocampus were measured. Microglia, insulin receptors, NLRP3, and IL-1β in the hippocampus of mice were evaluated by immunofluorescence or immunohistochemical staining., Results: As anticipated, dapagliflozin improved insulin resistance and glucose metabolism and reduced cognitive impairment in female mice fed with a HFD. In the hippocampus, dapagliflozin alleviated microglial activation yet did not reduce the secretion of inflammatory chemokines. Furthermore, it increased the expression of insulin receptor in the hippocampus of HFD-fed mice and decreased the expression of p-tau., Conclusions: Our results provide a foundation for the clinical application of SGLT2is as an adjuvant to slow down the progression of central degenerative diseases related to metabolic disorders, such as AD., (© 2025 The Author(s). Brain and Behavior published by Wiley Periodicals LLC.)